Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Steven A. Safren, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00218634
First received: September 20, 2005
Last updated: June 22, 2012
Last verified: June 2012
Results First Received: January 3, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Adherence
Depression
Heroin Dependence
Methadone
Motivational Interviewing
Substance-Related Disorders
Interventions: Behavioral: CBT-AD
Behavioral: ETAU

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First participants from methadone clinics, remainder from MGH or RIH clinics.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants had to screen for study inclusion/exclusion criteria before randomization.

Reporting Groups
  Description
CBT-AD Cognitive behavioral therapy for adherence and depression
ETAU Enhanced Treatment as Usual

Participant Flow:   Overall Study
    CBT-AD     ETAU  
STARTED     44     45  
COMPLETED     36     30  
NOT COMPLETED     8     15  
Lost to Follow-up                 8                 15  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
CBT-AD Cognitive behavioral therapy for adherence and depression
ETAU Enhanced Treatment as Usual
Total Total of all reporting groups

Baseline Measures
    CBT-AD     ETAU     Total  
Number of Participants  
[units: participants]
  44     45     89  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     44     45     89  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  47.05  ± 7.34     46.67  ± 7.05     46.85  ± 7.15  
Gender  
[units: participants]
     
Female     17     18     35  
Male     27     27     54  
Region of Enrollment  
[units: participants]
     
United States     44     45     89  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percent Medication Adherence at 3-month Follow-up Assessment   [ Time Frame: 3-month assessment ]

2.  Primary:   Percent Medication Adherence at 12-month Follow-up Assessment   [ Time Frame: 12-month follow-up assessment ]

3.  Secondary:   Clinician-assessed Depression Rating at 3 Month Follow-up Assessment   [ Time Frame: 3 month follow-up ]

4.  Secondary:   HIV Viral Load at 12-month Follow-up Assessment   [ Time Frame: 12-month follow-up assessment ]

5.  Secondary:   CD4+ Lymphocyte Count at 12-month Follow-up Assessment.   [ Time Frame: 12-month follow-up assessment ]

6.  Secondary:   Clinician-assessed Depression at 12-month Follow-up Assessment   [ Time Frame: 12-month follow-up assessment ]

7.  Secondary:   HIV Viral Load at 3-month Follow-up Assessment   [ Time Frame: 3-month assessment ]

8.  Secondary:   CD4+ Lymphocyte Count at 3-month Follow-up Assessment.   [ Time Frame: 3-month assessment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Steven Safren
Organization: Mass General Hospital
phone: 617 724 0817
e-mail: ssafren@partners.org


No publications provided by Massachusetts General Hospital

Publications automatically indexed to this study:

Responsible Party: Steven A. Safren, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00218634     History of Changes
Other Study ID Numbers: NIDA-18603-1, R01DA018603
Study First Received: September 20, 2005
Results First Received: January 3, 2012
Last Updated: June 22, 2012
Health Authority: United States: Federal Government